ic 50 curves analysis Search Results


ic 50 curves rac1 2 3  (Cytoskeleton Inc)
95
Cytoskeleton Inc ic 50 curves rac1 2 3
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Ic 50 Curves Rac1 2 3, supplied by Cytoskeleton Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ic 50 curves rac1 2 3/product/Cytoskeleton Inc
Average 95 stars, based on 1 article reviews
ic 50 curves rac1 2 3 - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
nonlinear dose-response curve analysis using graphpad prism 5.0  (GraphPad Software Inc)
90
GraphPad Software Inc nonlinear dose-response curve analysis using graphpad prism 5.0
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Nonlinear Dose Response Curve Analysis Using Graphpad Prism 5.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonlinear dose-response curve analysis using graphpad prism 5.0/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
nonlinear dose-response curve analysis using graphpad prism 5.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
graphpad prism 9.0  (GraphPad Software Inc)
90
GraphPad Software Inc graphpad prism 9.0
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Graphpad Prism 9.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/graphpad prism 9.0/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
graphpad prism 9.0 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prism 6.01  (GraphPad Software Inc)
90
GraphPad Software Inc prism 6.01
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Prism 6.01, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 6.01/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 6.01 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prism 4-parameter logistic non-linear regression analysis  (GraphPad Software Inc)
90
GraphPad Software Inc prism 4-parameter logistic non-linear regression analysis
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Prism 4 Parameter Logistic Non Linear Regression Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 4-parameter logistic non-linear regression analysis/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 4-parameter logistic non-linear regression analysis - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
nonlinear dose-response curve fitting analysis via graphpad prism v 4.0 software  (GraphPad Software Inc)
90
GraphPad Software Inc nonlinear dose-response curve fitting analysis via graphpad prism v 4.0 software
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Nonlinear Dose Response Curve Fitting Analysis Via Graphpad Prism V 4.0 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nonlinear dose-response curve fitting analysis via graphpad prism v 4.0 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
nonlinear dose-response curve fitting analysis via graphpad prism v 4.0 software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ic 50 values  (GraphPad Software Inc)
90
GraphPad Software Inc ic 50 values
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Ic 50 Values, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ic 50 values/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
ic 50 values - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prism 8.3 software  (GraphPad Software Inc)
90
GraphPad Software Inc prism 8.3 software
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Prism 8.3 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 8.3 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 8.3 software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prism probit analysis  (GraphPad Software Inc)
90
GraphPad Software Inc prism probit analysis
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Prism Probit Analysis, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism probit analysis/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism probit analysis - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
prism 6.0 software  (GraphPad Software Inc)
90
GraphPad Software Inc prism 6.0 software
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Prism 6.0 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/prism 6.0 software/product/GraphPad Software Inc
Average 90 stars, based on 1 article reviews
prism 6.0 software - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
pro software  (Molecular Devices LLC)
95
Molecular Devices LLC pro software
Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for <t>Rac1/2/;</t> right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.
Pro Software, supplied by Molecular Devices LLC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pro software/product/Molecular Devices LLC
Average 95 stars, based on 1 article reviews
pro software - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for Rac1/2/; right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.

Journal: Molecular cancer therapeutics

Article Title: Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer

doi: 10.1158/1535-7163.MCT-16-0442

Figure Lengend Snippet: Inhibitory effect of MBQ-167 on Rac and Cdc42 activation. MDA-MB-231 human breast cancer cells were treated for 24 h with 250 nM MBQ-167. A–C, The attached (A) and detached (D) cell populations were recovered and equal amounts of proteins subjected to pulldown assays using the p21-binding domain of PAK to isolate the GTP bound Rac and Cdc42. Cell lysates were western blotted with antibodies to Rac or Cdc42. Results from positive bands in western blots were quantified using image J. A, Left, Representative western blot for Rac1/2/; right, quantification of Rac activation at 24 h following 0 or 250nM MBQ-167. B, Left, Representative western blot for Cdc42; right, quantification of Cdc42 activation following 24 h treatment with 0 or 250 nM MBQ-167. The integrated density for active Rac or Cdc42 (GTP) was divided by the total Rac or Cdc42 from the same cell lysates. Rac or Cdc42 activity for each MBQ-167 treatment was divided by the vehicle controls for each experiment to obtain Relative Rac or Cdc42 activity. N=3, * = P < 0.05, *** = P < 0.001. Error bars represent ± S.E.M. C,D, MDA-MB-231 cells with vehicle control (0.1% DMSO) or varying concentrations of MBQ-167 (0–1000 nM) were treated for 24 hrs. Total cell lysates using combined attached and detached treated populations were subjected to the G-LISA Rac1/2/3 or Cdc42 activation assay. IC50 curves for percentage Rac (C) or Cdc42 (D) activation are relative to vehicle from three biological replicates each with two technical replicates. Error bars represent ± S.D. Four-parameter dose-response curves generated using GraphPad Prism® are shown.

Article Snippet: For the IC 50 curves Rac1/2/3 and Cdc42 activation was determined as described ( 16 ), using a G-LISA kit (Cytoskeleton, Inc., Denver, CO).

Techniques: Activation Assay, Binding Assay, Western Blot, Activity Assay, Control, Generated